Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors
Kardiotoxizität und kardiale Überwachung nach dem Einsatz von Radiotheranostika einschließlich 177Lu-PSMA bei Prostatakrebs und 177Lu-DOTATATE bei neuroendokrinen Tumoren
Esmail Jafari
1
The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy (MIRT), Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
,
Abdul Latif Amini
2
Bushehr Heart Medical center, Bushehr University of Medical Sciences, Bushehr, Iran
,
Hojjat Ahmadzadehfar
3
Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, Germany
,
Dara Bagheri
4
Department of Fisheries, Faculty of Agriculture and Natural Resources, Persian Gulf University, Bushehr, Iran
,
Majid Assadi
1
The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy (MIRT), Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran